BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Chronic urticaria clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for chronic urticaria: 48 (27 sponsors; 15 newly posted in the last 180 days, 2 stopped in the last 180 days; 8 new-entrant sponsors). Momentum score 30.2, rank 6 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 6, Phase 2 17, Phase 3 15, Phase 4 0, N/A 9.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Novartis Pharmaceuticals NVS | 14 | P3 6, NA 7, P2 1 | 3 | 1 |
| Celldex Therapeutics CLDX | 4 | P3 4 | 0 | 0 |
| Hangzhou Highlightll Pharmaceutical Co., Ltd | 3 | P3 1, P2 2 | 2 | 0 |
| Jemincare | 2 | P3 1, P2 1 | 0 | 0 |
| Longbio Pharma | 2 | P3 1, P1 1 | 1 | 0 |
| Shanghai Mabgeek Biotech.Co.Ltd | 2 | P3 1, P2 1 | 1 | 1 |
| Beijing InnoCare Pharma Tech Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Akeso new entrant | 1 | P2 1 | 1 | 0 |
| AlphaMol Science Ltd. (Shanghai) new entrant | 1 | P1 1 | 1 | 1 |
| ARS Pharmaceuticals, Inc. SPRY | 1 | P2 1 | 0 | 0 |
| Atridia Pty Ltd. new entrant | 1 | EARLY_P1 1 | 1 | 0 |
| Bambusa Therapeutics BBTX new entrant | 1 | P2 1 | 1 | 0 |
| BeOne Medicines ONC | 1 | P1 1 | 0 | 1 |
| Blueprint Medicines Corporation | 1 | P2 1 | 0 | 1 |
| Calixis Inc. new entrant | 1 | P2 1 | 1 | 0 |
| Celltrion HealthCare France | 1 | NA 1 | 0 | 0 |
| Chengdu Suncadia Medicine Co., Ltd. new entrant | 1 | P2 1 | 1 | 1 |
| Cogent Biosciences, Inc. COGT | 1 | P2 1 | 0 | 0 |
| Enanta Pharmaceuticals, Inc ENTA | 1 | P1 1 | 0 | 0 |
| Granular Therapeutics Limited | 1 | P1 1 | 0 | 0 |
| Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. new entrant | 1 | P1 1 | 1 | 0 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 1 | P2 1 | 0 | 0 |
| Keymed Biosciences Co.Ltd | 1 | P2 1 | 0 | 0 |
| Novelty Nobility, Inc. new entrant | 1 | P2 1 | 1 | 1 |
| Pfizer PFE | 1 | P2 1 | 0 | 1 |
New-entrant sponsors: Akeso, AlphaMol Science Ltd. (Shanghai), Atridia Pty Ltd., Bambusa Therapeutics, Calixis Inc., Chengdu Suncadia Medicine Co., Ltd., Hubei Bio-Pharmaceutical Industrial Technological Institute Inc., Novelty Nobility, Inc..
Recently stopped trials
- NCT06736262 Jasper Therapeutics, Inc. - terminated: Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns. A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants
- NCT07316114 Sanofi - terminated: Sponsor decision; the decision is not related to any safety concern. A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spont
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Chengdu Suncadia Medicine Co., Ltd. | NCT07613866 A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | not yet recruiting | 190 |
| 2026-12-25 est. | P2 | Pfizer PFE | NCT07219615 A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | Chronic Spontaneous Urticaria | recruiting | 200 |
| 2026-12-31 est. | P2 | Blueprint Medicines Corporation | NCT06931405 Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | Chronic Inducible Urticaria; Chronic Spontaneous Urticaria | active not recruiting | 105 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-03 est. | P3 | Novartis Pharmaceuticals NVS | NCT05677451 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response | Chronic Spontaneous Urticaria | active not recruiting | 100 |
| 2026-11-02 est. | P2 | Keymed Biosciences Co.Ltd | NCT07166211 Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) | Chronic Spontaneous Urticaria (CSU) | recruiting | 48 |
| 2026-09-27 est. | P1/P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT06864507 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic | Chronic Spontaneous Urticaria | not yet recruiting | 150 |
| 2026-08-12 | P3 | Celldex Therapeutics CLDX | NCT06445023 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | active not recruiting | 963 |
| 2026-08-04 | P3 | Celldex Therapeutics CLDX | NCT06455202 A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | Chronic Spontaneous Urticaria | active not recruiting | 976 |
| 2026-07-21 | P2 | Jasper Therapeutics, Inc. JSPR | NCT06736262 A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria | Urticaria Chronic | terminated | 67 |
| 2026-07-15 est. | P2 | Jemincare | NCT06509334 Trial of JYB1904 in Chronic Spontaneous Urticaria. | Chronic Spontaneous Urticaria | recruiting | 135 |
| 2026-07-08 | P1/P2 | Jasper Therapeutics, Inc. JSPR | NCT06162728 Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urt | Chronic Spontaneous Urticaria | completed | 87 |
| 2026-05-29 | P2 | Evommune, Inc. EVMN | NCT06873516 Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) | Chronic Spontaneous Urticaria | completed | 182 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "chronic urticaria"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.